Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 3/2024

09-02-2024 | Acne Inversa | Original Research Article

Autoimmune, Autoinflammatory Disease and Cutaneous Malignancy Associations with Hidradenitis Suppurativa: A Cross-Sectional Study

Authors: Hilliard T. Brydges, Ogechukwu C. Onuh, Rebecca Friedman, Joy Barrett, Rebecca A. Betensky, Catherine P. Lu, Avrom S. Caplan, Afsaneh Alavi, Ernest S. Chiu

Published in: American Journal of Clinical Dermatology | Issue 3/2024

Login to get access

Abstract

Background

Hidradenitis suppurativa (HS) is a debilitating cutaneous disease characterized by severe painful inflammatory nodules/abscesses. At present, data regarding the epidemiology and pathophysiology of this disease are limited.

Objective

To define the prevalence and comorbidity associations of HS.

Methods

This was a cross-sectional study of EPICTM Cosmos© examining over 180 million US patients. Prevalences were calculated by demographic and odds ratios (OR) and identified comorbidity correlations.

Results

All examined metabolism-related, psychological, and autoimmune/autoinflammatory (AI) diseases correlated with HS. The strongest associations were with pyoderma gangrenosum [OR 26.56; confidence interval (CI): 24.98–28.23], Down syndrome (OR 11.31; CI 10.93–11.70), and polycystic ovarian syndrome (OR 11.24; CI 11.09–11.38). Novel AI associations were found between HS and lupus (OR 6.60; CI 6.26–6.94) and multiple sclerosis (MS; OR 2.38; CI 2.29–2.48). Cutaneous malignancies were largely not associated in the unsegmented cohort; however, among Black patients, novel associations with melanoma (OR 2.39; CI 1.86–3.08) and basal cell carcinoma (OR 2.69; CI 2.15–3.36) were identified.

Limitations

International Classification of Diseases (ICD)-based disease identification relies on coding fidelity and diagnostic accuracy.

Conclusion

This is the first study to identify correlations between HS with melanoma and basal cell carcinoma (BCC) among Black patients as well as MS and lupus in all patients with HS.
Appendix
Available only for authorised users
Literature
1.
Constantinou CA, Fragoulis GE, Nikiphorou E. Hidradenitis suppurativa: infection, autoimmunity, or both? Ther Adv Musculoskelet Dis. 2019;11:1759720X19895488.
2.
Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045–58.PubMedCrossRef
3.
Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35(1):50–61.PubMedCrossRef
4.
Tiri H, Jokelainen J, Timonen M, Tasanen K, Huilaja L. Substantially reduced life expectancy in patients with hidradenitis suppurativa: a Finnish nationwide registry study. Br J Dermatol. 2019;180(6):1543–4.PubMedCrossRef
5.
Garg A, Malviya N, Strunk A, Wright S, Alavi A, Alhusayen R, et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022;86(5):1092–101.PubMedCrossRef
6.
Melnik BC, John SM, Chen W, Plewig G. T helper 17 cell/regulatory T-cell imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities. Br J Dermatol. 2018;179(2):260–72.PubMed
7.
Preda-Naumescu A, Ahmed HN, Mayo TT, Yusuf N. Hidradenitis suppurativa: pathogenesis, clinical presentation, epidemiology, and comorbid associations. Int J Dermatol. 2021;60(11):e449–58.PubMedCrossRef
8.
Seyed Jafari SM, Hunger RE, Schlapbach C. Hidradenitis suppurativa: current understanding of pathogenic mechanisms and suggestion for treatment algorithm. Front Med. 2020;7:68.CrossRef
9.
Remedios KA, Zirak B, Sandoval PM, Lowe MM, Boda D, Henley E, et al. The TNFRSF members CD27 and OX40 coordinately limit T(H)17 differentiation in regulatory T cells. Sci Immunol. 2018;3(30).
10.
Yidana DB. Hidradenitis suppurativa—the role of interleukin-17, the aryl hydrocarbon receptor and the link to a possible fungal aetiology. Med Hypotheses. 2021;149: 110530.PubMedCrossRef
11.
Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022;603(7900):321–7.PubMedPubMedCentralCrossRef
12.
Frew JW, Navrazhina K, Marohn M, Lu PC, Krueger JG. Contribution of fibroblasts to tunnel formation and inflammation in hidradenitis suppurativa/ acne inversa. Exp Dermatol. 2019;28(8):886–91.PubMedPubMedCentralCrossRef
13.
Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J. 2014;90(1062):216–21 (quiz 20).
14.
Tarabichi Y, Frees A, Honeywell S, Huang C, Naidech AM, Moore JH, Kaelber DC. The cosmos collaborative: a vendor-facilitated electronic health record data aggregation platform. ACI Open. 2021;5(1):e36–46.PubMedPubMedCentralCrossRef
15.
16.
Son M, Gallagher K, Lo JY, Lindgren E, Burris HH, Dysart K, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy outcomes in a US population. Obstet Gynecol. 2021;138(4):542–51.PubMedPubMedCentralCrossRef
17.
Handley SC, Gallagher K, Breden A, Lindgren E, Lo JY, Son M, et al. Birth hospital length of stay and rehospitalization during COVID-19. Pediatrics. 2022;149(1).
18.
Handley SC, Gallagher K, Lindgren E, Lo JY, Burris HH, Dysart KC, et al. Postpartum length of stay and hospital readmission before and during the coronavirus disease 2019 (COVID-19) pandemic. Obstet Gynecol. 2022;139(3):381–90.PubMedCrossRef
19.
Plumb ID, Feldstein LR, Barkley E, Posner AB, Bregman HS, Hagen MB, Gerhart JL. Effectiveness of COVID-19 mRNA vaccination in preventing COVID-19-associated hospitalization among adults with previous SARS-CoV-2 infection—United States, June 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(15):549–55.PubMedPubMedCentralCrossRef
20.
Kranyak A, Rork J, Levy J, Burdick TE. Alopecia areata and thyroid screening in down syndrome: leveraging Epic Cosmos Dataset. J Am Acad Dermatol. 2023;89:360.PubMedCrossRef
21.
Krimpuri R, Youngs C, Emerman C. Initiation of medication for alcohol use disorder for inpatients with alcohol withdrawal syndromes. J Stud Alcohol Drugs. 2022.
22.
Pham HH, Sandberg N, Trinkl J, Thayer J. Racial and ethnic differences in rates and age of diagnosis of autism spectrum disorder. JAMA Netw Open. 2022;5(10): e2239604.PubMedPubMedCentralCrossRef
23.
Kim EG, Kaelber DC. Phenotypic prevalence of obesity and metabolic syndrome among an underdiagnosed and underscreened population of over 50 million children and adults. Front Genet. 2022;13: 961116.PubMedPubMedCentralCrossRef
24.
Sachdeva M, Shah M, Alavi A. Race-specific prevalence of hidradenitis suppurativa. J Cutan Med Surg. 2021;25(2):177–87.PubMedCrossRef
25.
Shlyankevich J, Chen AJ, Kim GE, Kimball AB. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol. 2014;71(6):1144–50.PubMedCrossRef
26.
Phan K, Huo YR, Smith SD. Hidradenitis suppurativa and psychiatric comorbidities, suicides and substance abuse: systematic review and meta-analysis. Ann Transl Med. 2020;8(13):821.PubMedPubMedCentralCrossRef
27.
Kohorst JJ, Kimball AB, Davis MD. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S27-35.PubMedCrossRef
28.
Calao M, Wilson JL, Spelman L, Billot L, Rubel D, Watts AD, Jemec GBE. Hidradenitis suppurativa (HS) prevalence, demographics and management pathways in Australia: a population-based cross-sectional study. PLoS ONE. 2018;13(7): e0200683.PubMedPubMedCentralCrossRef
29.
Sabat R, Jemec GBE, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18.PubMedCrossRef
30.
Yang JH, Moon J, Kye YC, Kim KJ, Kim MN, Ro YS, et al. Demographic and clinical features of hidradenitis suppurativa in Korea. J Dermatol. 2018;45(12):1389–95.PubMedCrossRef
31.
Deckers IE, Mihajlović D, Prens EP, Boer J. Hidradenitis suppurativa: a pilot study to determine the capability of patients to self-assess their Hurley stage. Br J Dermatol. 2015;172(5):1418–9.PubMedCrossRef
32.
Ingram JR, Jenkins-Jones S, Knipe DW, Morgan CLI, Cannings-John R, Piguet V. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018;178(4):917–24.PubMedCrossRef
33.
Cices A, Ibler E, Majewski S, Huynh T, Sable KA, Brieva J, et al. Hidradenitis suppurativa association at the time of, or subsequent to, diagnosis of inflammatory bowel disease in a large U.S. patient population. J Eur Acad Dermatol Venereol. 2017;31(7):e311–e2.
34.
Tannenbaum R, Strunk A, Garg A. Overall and subgroup prevalence of pyoderma gangrenosum among patients with hidradenitis suppurativa: a population-based analysis in the United States. J Am Acad Dermatol. 2019;80(6):1533–7.PubMedCrossRef
35.
Deckers IE, Benhadou F, Koldijk MJ, Del Marmol V, Horváth B, Boer J, et al. Inflammatory bowel disease is associated with hidradenitis suppurativa: results from a multicenter cross-sectional study. J Am Acad Dermatol. 2017;76(1):49–53.PubMedCrossRef
36.
Phan K, Charlton O, Smith SD. Hidradenitis suppurativa and metabolic syndrome—systematic review and adjusted meta-analysis. Int J Dermatol. 2019;58(10):1112–7.PubMedCrossRef
37.
Lee JH, Kwon HS, Jung HM, Kim GM, Bae JM. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. J Eur Acad Dermatol Venereol. 2018;32(10):1784–90.PubMedCrossRef
38.
Mintoff D, Benhadou F, Pace NP, Frew JW. Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects. Int J Dermatol. 2022;61(10):1175–86.PubMedCrossRef
39.
Jalenques I, Ciortianu L, Pereira B, D’Incan M, Lauron S, Rondepierre F. The prevalence and odds of anxiety and depression in children and adults with hidradenitis suppurativa: systematic review and meta-analysis. J Am Acad Dermatol. 2020;83(2):542–53.PubMedCrossRef
40.
Jung JM, Lee KH, Kim YJ, Chang SE, Lee MW, Choi JH, et al. Assessment of overall and specific cancer risks in patients with hidradenitis suppurativa. JAMA Dermatol. 2020;156(8):844–53.PubMedCrossRef
41.
Crowley JJ, Mekkes JR, Zouboulis CC, Scheinfeld N, Kimball A, Sundaram M, et al. Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities. Br J Dermatol. 2014;171(6):1561–5.PubMedPubMedCentralCrossRef
42.
Poizeau F, Sbidian E, Mircher C, Rebillat AS, Chosidow O, Wolkenstein P, et al. Prevalence and description of hidradenitis suppurativa in Down syndrome: a cross-sectional study of 783 subjects. Acta Derm Vener. 2019;99(3):351–2.CrossRef
43.
Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153(8):760–4.PubMedPubMedCentralCrossRef
44.
Sechi A, Guglielmo A, Patrizi A, Savoia F, Cocchi G, Leuzzi M, Chessa MA. Disseminate recurrent folliculitis and hidradenitis suppurativa are associated conditions: results from a retrospective study of 131 patients with down syndrome and a cohort of 12,351 pediatric controls. Dermatol Pract Concept. 2019;9(3):187–94.PubMedPubMedCentralCrossRef
45.
Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County. Minnesota J Invest Dermatol. 2013;133(1):97–103.PubMedCrossRef
46.
Shavit E, Dreiher J, Freud T, Halevy S, Vinker S, Cohen AD. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29(2):371–6.PubMedCrossRef
47.
48.
Altman DG, Bland JM. How to obtain the confidence interval from a P value. Br Med J. 2011;343: d2090.CrossRef
49.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57(1):289–300.CrossRef
50.
51.
Carmona-Rivera C, O'Neil LJ, Patino-Martinez E, Shipman WD, Zhu C, Li QZ, et al. Autoantibodies Present in Hidradenitis Suppurativa Correlate with Disease Severity and Promote the Release of Proinflammatory Cytokines in Macrophages. J Invest Dermatol. 2022;142(3 Pt B):924–35.
52.
Pironi D, Caruso F, Panarese A, Vendettuoli M, Mascagni D, Moraldi L, Filippini A. Chronic hidradenitis suppurativa in the inguinal, perineal and scrotal regions. A case report and review of the literature. Ann Ital Chir. 2010;81(6):465–70.
53.
Saygın D, Syed AU, Lowder CY, Srivastava S, Maya JJ, Hajj-Ali RA. Characteristics of inflammatory eye disease associated with hidradenitis suppurativa. Eur J Rheumatol. 2018;5(3):165–8.
54.
Posso-De Los Rios CJ, Sarfo A, Ghias M, Alhusayen R, Hamzavi I, Lowes MA, Alavi A. Proceeding report of the third symposium on hidradenitis suppurativa advances (SHSA) 2018. Exp Dermatol. 2019;28(7):769–75.
55.
Carmona-Rivera C, O’Neil LJ, Patino-Martinez E, Shipman WD, Zhu C, Li QZ, et al. Autoantibodies present in hidradenitis suppurativa correlate with disease severity and promote the release of proinflammatory cytokines in macrophages. J Invest Dermatol. 2022;142(3 Pt B):924–35.PubMedCrossRef
56.
Pironi D, Caruso F, Panarese A, Vendettuoli M, Mascagni D, Moraldi L, Filippini A. Chronic hidradenitis suppurativa in the inguinal, perineal and scrotal regions A case report and review of the literature. Ann Ital Chir. 2010;81(6):465–70.PubMed
57.
Saygın D, Syed AU, Lowder CY, Srivastava S, Maya JJ, Hajj-Ali RA. Characteristics of inflammatory eye disease associated with hidradenitis suppurativa. Euro J Rheumat. 2018;5(3):165–8.CrossRef
58.
Ross Y, Ballou S. Association of hidradenitis suppurativa with autoimmune disease and autoantibodies. Rheumatol Adv Pract. 2022;6(2):rkab108.PubMedCrossRef
59.
Lee JW, Heo YW, Lee JH, Lee S. Epidemiology and comorbidity of hidradenitis suppurativa in Korea for 17 years: a nationwide population-based cohort study. J Dermatol. 2023;50(6):778–86.PubMedCrossRef
60.
Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(9):515–32.PubMedPubMedCentralCrossRef
61.
Jorge A, Castro VM, Barnado A, Gainer V, Hong C, Cai T, et al. Identifying lupus patients in electronic health records: development and validation of machine learning algorithms and application of rule-based algorithms. Semin Arthritis Rheum. 2019;49(1):84–90.PubMedPubMedCentralCrossRef
62.
Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology. 2017;56(11):1945–61.PubMedCrossRef
63.
Izmirly PM, Parton H, Wang L, McCune WJ, Lim SS, Drenkard C, et al. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021;73(6):991–6.PubMedPubMedCentralCrossRef
64.
65.
Sachdeva M, Mufti A, Zaaroura H, Abduelmula A, Lansang RP, Bagit A, Alhusayen R. Squamous cell carcinoma arising within hidradenitis suppurativa: a literature review. Int J Dermatol. 2021;60(11):e459–65.PubMedCrossRef
66.
Agbai ON, Buster K, Sanchez M, Hernandez C, Kundu RV, Chiu M, et al. Skin cancer and photoprotection in people of colOR a review and recommendations for physicians and the public. J Am Acad Dermatol. 2014;70(4):748–62.PubMedCrossRef
67.
Jourabchi N, Fischer AH, Cimino-Mathews A, Waters KM, Okoye GA. Squamous cell carcinoma complicating a chronic lesion of hidradenitis suppurativa: a case report and review of the literature. Int Wound J. 2017;14(2):435–8.PubMedCrossRef
68.
Penno CA, Jäger P, Laguerre C, Hasler F, Hofmann A, Gass SK, et al. Lipidomics profiling of hidradenitis suppurativa skin lesions reveals lipoxygenase pathway dysregulation and accumulation of proinflammatory leukotriene B4. J Invest Dermatol. 2020;140(12):2421-32.e10.PubMedCrossRef
69.
Matsushita M, Pearce EJ. Disrupting metabolism to treat autoimmunity. Science. 2018;360(6387):377–8.PubMedCrossRef
70.
Yu W, Barrett J, Liu P, Parameswaran A, Chiu ES, Lu CP. Novel evidence of androgen receptor immunoreactivity in skin tunnels of hidradenitis suppurativa: assessment of sex and individual variability. Br J Dermatol. 2021;185(4):855–8.PubMedCrossRef
71.
Navrazhina K, Garcet S, Zheng X, Hur HB, Frew JW, Krueger JG. High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression. J Allergy Clin Immunol. 2022;149(1):135-44.e12.PubMedCrossRef
72.
Tzellos T, Zouboulis CC. Which hidradenitis suppurativa comorbidities should I take into account? Exp Dermatol. 2022;31(Suppl 1):29–32.PubMedCrossRef
73.
74.
75.
Loevinger BL, Muller D, Alonso C, Coe CL. Metabolic syndrome in women with chronic pain. Metab Clin Exp. 2007;56(1):87–93.PubMedCrossRef
76.
Kwak Y, Kim Y, Kwon SJ, Chung H. Mental health status of adults with cardiovascular or metabolic diseases by gender. Int J Environ Res Public Health. 2021;18(2):514.PubMedPubMedCentralCrossRef
77.
Moreau M, Benhaddou S, Dard R, Tolu S, Hamzé R, Vialard F, et al. Metabolic diseases and down syndrome: how are they linked together? Biomedicines. 2021;9(2):221.PubMedPubMedCentralCrossRef
Metadata
Title
Autoimmune, Autoinflammatory Disease and Cutaneous Malignancy Associations with Hidradenitis Suppurativa: A Cross-Sectional Study
Authors
Hilliard T. Brydges
Ogechukwu C. Onuh
Rebecca Friedman
Joy Barrett
Rebecca A. Betensky
Catherine P. Lu
Avrom S. Caplan
Afsaneh Alavi
Ernest S. Chiu
Publication date
09-02-2024
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 3/2024
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-024-00844-5

Other articles of this Issue 3/2024

American Journal of Clinical Dermatology 3/2024 Go to the issue

Review Article

OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target

Review Article

Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma

Review Article

Field Cancerization Therapies for the Management of Actinic Keratosis: An Updated Review

Review Article

The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature

Correction

Correction to: OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target

Original Research Article

Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)